Literature DB >> 24095978

The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation.

Eugenio Barone1, Fabio Di Domenico2, Cesare Mancuso3, D Allan Butterfield4.   

Abstract

Alzheimer disease (AD) is the most common form of dementia among the elderly and is characterized by progressive loss of memory and cognition. These clinical features are due in part to the increase of reactive oxygen and nitrogen species that mediate neurotoxic effects. The up-regulation of the heme oxygenase-1/biliverdin reductase-A (HO-1/BVR-A) system is one of the earlier events in the adaptive response to stress. HO-1/BVR-A reduces the intracellular levels of pro-oxidant heme and generates equimolar amounts of the free radical scavengers biliverdin-IX alpha (BV)/bilirubin-IX alpha (BR) as well as the pleiotropic gaseous neuromodulator carbon monoxide (CO) and ferrous iron. Two main and opposite hypotheses for a role of the HO-1/BVR-A system in AD propose that this system mediates neurotoxic and neuroprotective effects, respectively. This apparent controversy was mainly due to the fact that for over about 20years HO-1 was the only player on which all the analyses were focused, excluding the other important and essential component of the entire system, BVR. Following studies from the Butterfield laboratory that reported alterations in BVR activity along with decreased phosphorylation and increased oxidative/nitrosative post-translational modifications in the brain of subjects with AD and amnestic mild cognitive impairment (MCI) subjects, a debate was opened on the real pathophysiological and clinical significance of BVR-A. In this paper we provide a review of the main discoveries about the HO/BVR system in AD and MCI, and propose a mechanism that reconciles these two hypotheses noted above of neurotoxic and the neuroprotective aspects of this important stress responsive system.
© 2013.

Entities:  

Keywords:  3-NT; 3-nitrotyrosine; 4-hydroxy-2-nonenal; ARE; Aging; Alzheimer disease; BVR-A; Biliverdin reductase; HNE; HO-1/2; Heme oxygenase; Mild cognitive impairment; Oxidative stress; PC; antioxidant responsive elements; biliverdin reductase isoform A; heme oxygenase isoform 1 or 2; protein carbonyls

Mesh:

Substances:

Year:  2013        PMID: 24095978      PMCID: PMC3877707          DOI: 10.1016/j.nbd.2013.09.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  220 in total

1.  Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia.

Authors:  Konukoğlu Dildar; Firtina Sinem; Erkol Gökhan; Yağiz Orhan; Manga Filiz
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

3.  Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study.

Authors:  Eric G Rodriguez; Hiroko H Dodge; Maria A Birzescu; Gary P Stoehr; Mary Ganguli
Journal:  J Am Geriatr Soc       Date:  2002-11       Impact factor: 5.562

Review 4.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

Review 5.  The heme oxygenase/biliverdin reductase pathway in drug research and development.

Authors:  C Mancuso; E Barone
Journal:  Curr Drug Metab       Date:  2009-07-14       Impact factor: 3.731

Review 6.  The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches.

Authors:  Carl W Cotman; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

7.  Reductive stress in young healthy individuals at risk of Alzheimer disease.

Authors:  Mari-Carmen Badía; Esther Giraldo; Francisco Dasí; Dolores Alonso; Jose M Lainez; Ana Lloret; Jose Viña
Journal:  Free Radic Biol Med       Date:  2013-05-07       Impact factor: 7.376

Review 8.  Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.

Authors:  Velandai Srikanth; Annette Maczurek; Thanh Phan; Megan Steele; Bernadette Westcott; Damian Juskiw; Gerald Münch
Journal:  Neurobiol Aging       Date:  2009-05-22       Impact factor: 4.673

9.  Biliverdin reductase: more than a namesake - the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C.

Authors:  Peter E M Gibbs; Cicerone Tudor; Mahin D Maines
Journal:  Front Pharmacol       Date:  2012-03-13       Impact factor: 5.810

10.  Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients.

Authors:  Laure Saint-Aubert; Emmanuel J Barbeau; Patrice Péran; Federico Nemmi; Celine Vervueren; Helene Mirabel; Pierre Payoux; Anne Hitzel; Fabrice Bonneville; Raluca Gramada; Mathieu Tafani; Christian Vincent; Michele Puel; Sophie Dechaumont; Francois Chollet; Jeremie Pariente
Journal:  EJNMMI Res       Date:  2013-06-03       Impact factor: 3.138

View more
  41 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Interaction of human biliverdin reductase with Akt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism of Akt activation.

Authors:  Tihomir Miralem; Nicole Lerner-Marmarosh; Peter E M Gibbs; Jermaine L Jenkins; Chelsea Heimiller; Mahin D Maines
Journal:  FASEB J       Date:  2016-05-10       Impact factor: 5.191

Review 3.  Research Progress on Alzheimer's Disease and Resveratrol.

Authors:  Yan Yan; Huihuang Yang; Yuxun Xie; Yuanlin Ding; Danli Kong; Haibing Yu
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

Review 4.  Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 5.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

6.  Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ -activated BV-2 microglia cells.

Authors:  Makini K Cobourne-Duval; Equar Taka; Patricia Mendonca; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-05-04       Impact factor: 3.478

Review 7.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

Review 8.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

9.  Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53.

Authors:  Eugenio Barone; Giovanna Cenini; Fabio Di Domenico; Teresa Noel; Chi Wang; Marzia Perluigi; Daret K St Clair; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2015-08-06       Impact factor: 4.164

Review 10.  Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Authors:  Eugenio Barone; Fabio Di Domenico; D Allan Butterfield
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.